Abstract
In this issue of Blood, Wang and colleagues from the Mayo Clinic and the University of Iowa, describe the outcomes of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) and treated in the era of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) who are also found to have an underlying indolent lymphoma in the lymph nodes or the bone marrow.
Original language | English |
---|---|
Pages (from-to) | 1273-1274 |
Number of pages | 2 |
Journal | Blood |
Volume | 134 |
Issue number | 16 |
DOIs | |
State | Published - Oct 17 2019 |